查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1423610

2030 年祛痰藥市場預測：按產品、劑型、藥物類型、通路、最終用戶和地區進行的全球分析

Expectorant Drugs Market Forecasts to 2030 - Global Analysis By Product (Prescription Drug and Over the Counter (Otc)), Dosage Form (Oral Solid, Oral Liquid and Inhalant), Drug Type, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球祛痰藥市場規模為 171.6 億美元，預計到 2030 年將達到 453.8 億美元，預測期內複合年成長率為 14.9%。

祛痰藥是主要用於促進清除呼吸道（尤其是呼吸系統）中的黏液和分泌物的藥物。這些藥物的作用是稀釋或鬆弛肺部黏液，使其更容易排放。它通常用於緩解與呼吸道疾病相關的症狀，例如咳嗽、鼻塞和呼吸道感染疾病。

根據美國國家生物技術資訊中心發布的資料，全球基層醫療醫生就診中約有 8% 是因咳嗽引起的。

呼吸道疾病盛行率上升

隨著患有支氣管炎、慢性阻塞性肺病、氣喘、呼吸道感染疾病等呼吸系統疾病的人數增加，對藥品特別是祛痰藥的需求也不斷增加。這些藥物在控制這些疾病的特徵症狀（如黏液分泌過多、咳嗽和胸悶）方面發揮著至關重要的作用。由於空氣污染、生活方式改變和感染疾病因素，呼吸道疾病變得更加常見，對祛痰藥緩解症狀和改善呼吸道健康的持續需求正在推動市場成長。

副作用增加

祛痰藥市場受到日益增加的副作用的嚴重限制。由於這些藥物旨在透過稀釋黏液來緩解呼吸道症狀，因此越來越多的副作用（例如噁心、頭暈和過敏反應）報告影響了患者的耐受性和依從性。副作用發生率的增加可能會抑制患者的醫囑遵從性，降低對這些藥物的信心，並影響市場需求。

技術進步

持續的技術創新是開發先進藥物配方、改進給藥系統和增強祛痰藥功效的驅動力。新技術正在創造創新的配方，促進有針對性的藥物輸送到受影響的呼吸道區域，並最佳化治療結果和患者的依從性。此外，個人化醫學和藥物基因組學的進步可能會帶來量身定做的祛痰治療，確保更有效和個人化的治療方法。這些進步的結合將解決未滿足的醫療需求，並推動祛痰藥市場的成長和創新。

監管障礙

複雜的法律規範、不同的地區要求和延長的核准時間是引入新祛痰藥的障礙。克服這些障礙需要在研發方面進行大量投資、嚴格遵守嚴格的監管準則以及與監管機構的有效合作。如果無法克服這些挑戰，可能會阻礙創新祛痰藥的及時推出並限制市場成長。

COVID-19 的影響

隨著人們開始關注與 COVID-19 相關的咳嗽和胸悶等呼吸道症狀，對祛痰藥的需求激增。這場大流行促使對呼吸系統健康的研究增加，這可能會導致新開發。此外，即使在大流行的早期階段，對祛痰藥的需求也可能會持續存在，因為 COVID-19 對呼吸道健康有長期影響，且呼吸道問題可能持續存在。

黏液溶解劑領域預計將在預測期內成為最大的領域

據估計，粘液溶解劑領域佔最大佔有率。黏液溶解藥物包括溴己新、乙醯半胱胺酸和氨溴索等藥物，它們透過破壞黏液中的化學鍵來降低黏液的黏度，使其更容易排放。黏液溶解劑用於治療多種呼吸系統疾病，如慢性支氣管炎、COPD（慢性阻塞性肺病）和囊腫纖維化，以幫助排放多餘的黏液並緩解充血症狀。此外，標靶和改變黏液特性的能力使其成為治療呼吸道疾病的重要因素。

預計醫院部門在預測期內將呈現最高的複合年成長率

預計醫院產業在預測期內將出現良好的成長。醫院是祛痰藥的主要買家和賣家，因為它們是呼吸系統疾病診斷和治療的主要中心。醫院採購各種祛痰藥來治療急性和慢性呼吸道疾病的患者，包括肺炎、支氣管炎和慢性阻塞性肺病惡化。此外，醫院保持充足的這些藥物庫存，以滿足住院患者呼吸護理、急診治療和慢性病管理的多樣化呼吸健康需求，從而擴大了祛痰藥市場。

比最大的地區

由於呼吸道疾病的增加、污染水平的上升以及遭受季節性性行為感染的人口的增加，亞太地區在預測期內佔據了最大的市場佔有率。此外，都市化、生活方式的改變和環境污染物等因素會導致呼吸道疾病，進而推動對祛痰藥的需求。主要市場參與者投資研發以探索和獲得負擔得起的醫療保健，促進了亞太地區祛痰藥市場的快速成長。我們滿足您的健康需求。

複合年成長率最高的地區：

由於支氣管炎、流感和過敏等疾病的流行，預計北美在預測期內將出現盈利成長。該地區強大的醫療基礎設施、先進的藥物研究以及意識層級正在推動市場成長。此外，藥物開發的策略性舉措、強力的法規結構、專注於技術創新和產品多元化的主要市場參與者的存在進一步推動了北美祛痰藥市場的發展。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球祛痰藥市場：按產品

  • 處方藥
  • 店面銷售(OTC)

第6章全球祛痰藥市場：按劑型

  • 口服固態
  • 口服液
  • 吸入劑

第7章全球祛痰藥市場：依藥物類型

  • 分泌刺激劑
    • 檸檬酸鉀
    • 檸檬酸鈉
    • 氯化銨
  • 黏液溶解劑
    • 溴己新
    • 氨溴索
    • 碳半胱氨酸尿素
    • 乙醯半胱胺酸
  • 其他類型的藥物

第8章全球祛痰藥市場：依通路分類

  • 藥局
  • 零售店
  • 網路藥房
  • 其他分銷管道

第9章全球祛痰藥市場：依最終用戶分類

  • 醫院
  • 專業中心
  • 居家護理
  • 其他最終用戶

第10章全球祛痰藥市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司簡介

  • Abbott Laboratories
  • Astrazeneca Plc.
  • Acella Pharmaceuticals LLC
  • Cipla Limited
  • Beckman Coulter Inc.
  • Mylan NV
  • GSK plc
  • Glenmark Pharmaceuticals Limited
  • Johnson and Johnson
  • Novartis International AG
  • Merck KGaA
  • Pfizer inc
  • Sanofi SA
  • Vernalis plc
  • Proctor and Gamble Co
  • Dahur india Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Tris Pharma Inc.
  • Aurobindo Pharma Ltd
  • Biocon
Product Code: SMRC24844

According to Stratistics MRC, the Global Expectorant Drugs Market is accounted for $17.16 billion in 2023 and is expected to reach $45.38 billion by 2030 growing at a CAGR of 14.9% during the forecast period. Expectorant drugs are medications primarily used to facilitate the removal of mucus and secretions from the airways, particularly in the respiratory tract. These drugs work by thinning and loosening mucus in the lungs, making it easier to cough up and expel. They are commonly used to alleviate symptoms associated with respiratory conditions such as cough, congestion, and respiratory infections.

According to data released by the National Center for Biotechnology Information, cough accounted for about 8% of all consultations with primary care physicians worldwide.

Market Dynamics:

Driver:

Rising prevalence of respiratory conditions

With an increasing number of individuals affected by respiratory ailments like bronchitis, COPD, asthma, and respiratory infections, the demand for medications, particularly expectorant drugs, rises correspondingly. These medications play a pivotal role in managing the hallmark symptoms of these conditions, such as excessive mucus production, coughing, and chest congestion. As respiratory illnesses become more commonplace due to factors like air pollution, changing lifestyles, and infectious agents, the consistent need for expectorant drugs to alleviate symptoms and improve respiratory health drives market growth.

Restraint:

Increased side effects

The market for expectorant drugs is severely constrained by the growing number of adverse effects. As these medications aim to alleviate respiratory symptoms by thinning mucus, the rise in reported adverse effects like nausea, dizziness, or allergic reactions impacts patient tolerance and compliance. Heightened occurrences of side effects can deter patient adherence, leading to reduced confidence in these medications and potentially affecting market demand.

Opportunity:

Advancements in technology

Ongoing innovations drive the development of advanced drug formulations, improved delivery systems, and enhanced efficacy of expectorant medications. Novel technologies facilitate targeted drug delivery to affected respiratory areas, creating innovative formulations that optimise treatment outcomes and patient compliance. Additionally, advancements in personalised medicine and pharmacogenomics may lead to tailored expectorant therapies, ensuring more effective and personalised treatment approaches. Embracing these advancements addresses unmet medical needs, fostering growth and innovation in the expectorant drugs market.

Threat:

Regulatory hurdles

Complex regulatory frameworks, diverse regional requirements, and extended approval timelines create obstacles for introducing new expectorant medications. Overcoming these hurdles demands substantial investments in research and development, meticulous adherence to stringent regulatory guidelines, and effective collaboration with regulatory bodies. Failure to navigate these challenges can impede the timely introduction of innovative expectorant drugs, limiting market growth.

Covid-19 Impact

There was a surge in demand for expectorant drugs due to the emphasis on managing respiratory symptoms associated with COVID-19, such as cough and chest congestion. The pandemic prompted increased research into respiratory health, potentially leading to the development of new and improved expectorant drugs or formulations. Furthermore, during the initial pandemic phase, there may be a continuing need for expectorant medications due to the COVID-19's long-lasting effects on respiratory health and possible long-term respiratory problems.

The mucolytics segment is expected to be the largest during the forecast period

The mucolytics segment is estimated to hold the largest share. Mucolytics contain agents such as bromhexine, acetylcysteine, or ambroxol that work by disrupting the chemical bonds within mucus, making it less viscous and easier to expel through coughing. Mucolytics find application in various respiratory conditions like chronic bronchitis, COPD (chronic obstructive pulmonary disease), and cystic fibrosis, aiding in the clearance of excessive mucus and alleviating symptoms of congestion. Furthermore, their ability to target and modify the properties of mucus makes them a crucial component in managing respiratory disorders.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to have lucrative growth during the forecast period. Hospitals serve as major purchasers and distributors of expectorant drugs due to their role as primary centres for diagnosing and treating respiratory conditions. They procure a wide range of expectorant medications to manage patients with acute and chronic respiratory ailments, including pneumonia, bronchitis, and COPD exacerbations. In addition, hospitals maintain adequate stocks of these drugs to address the diverse respiratory health needs of patients admitted for respiratory care, emergency treatments, or chronic disease management, thereby significantly contributing to the demand within the expectorant drug market.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to rising respiratory ailments, increasing pollution levels, and a larger population affected by seasonal infections. Furthermore, factors like urbanisation, changing lifestyles, and environmental pollutants contribute to respiratory issues, driving the demand for expectorant medications. Initiatives for affordable healthcare access and the presence of key market players investing in research and development contribute to the region's burgeoning expectorant drug market, catering to the diverse respiratory health needs of the Asia Pacific population.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period, due to prevalent conditions like bronchitis, flu, and allergies. The region's robust healthcare infrastructure, advanced pharmaceutical research, and high awareness levels among the population about managing respiratory health issues foster market growth. Moreover, strategic initiatives for drug development, strong regulatory frameworks, and the presence of key market players focusing on innovation and product diversification further propel the North American expectorant drug market.

Key players in the market

Some of the key players in the Expectorant Drugs Market include Abbott Laboratories, Astrazeneca Plc., Acella Pharmaceuticals LLC, Cipla Limited, Beckman Coulter Inc., Mylan N.V., GSK plc, Glenmark Pharmaceuticals Limited, Johnson and Johnson, Novartis International AG, Merck KGaA, Pfizer inc, Sanofi SA, Vernalis plc, Proctor and Gamble Co, Dahur india Ltd, Teva Pharmaceutical Industries Ltd., Tris Pharma Inc., Aurobindo Pharma Ltd and Biocon.

Key Developments:

In October 2023, Efficient Laboratories, a Puerto Rican firm that distributes its brands of healthcare products, launched a new product, ROMPR PECHITO, an OTC medicine for children to relieve cold symptoms.

In September 2023, Genexa announced new clean over-the-counter (OTC) kids' medicines, further strengthening its leading role in bringing consumers clean, safe, and effective medications.

Products Covered:

  • Prescription Drug
  • Over the Counter (Otc)

Dosage Forms Covered:

  • Oral Solid
  • Oral Liquid
  • Inhalant

Drug Types Covered:

  • Secretion Enhancer
  • Mucolytics
  • Other Drug Types

Distribution Channels Covered:

  • Drug Store
  • Retail Store
  • Online Pharmacies
  • Other Distribution Channels

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Expectorant Drugs Market, By Product

  • 5.1 Introduction
  • 5.2 Prescription Drug
  • 5.3 Over The Counter (Otc)

6 Global Expectorant Drugs Market, By Dosage Form

  • 6.1 Introduction
  • 6.2 Oral Solid
  • 6.7 Oral Liquid
  • 6.8 Inhalant

7 Global Expectorant Drugs Market, By Drug Type

  • 7.1 Introduction
  • 7.2 Secretion Enhancer
    • 7.2.1 Potassium Citrate
    • 7.2.2 Sodium Citrate
    • 7.2.3 Ammonium Chloride
  • 7.3 Mucolytics
    • 7.3.1 Bromhexine
    • 7.3.2 Ambroxol
    • 7.3.3 Carbocisteineurine
    • 7.3.4 Acetyl Cysteine
  • 7.4 Other Drug Types

8 Global Expectorant Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Drug Store
  • 8.3 Retail Store
  • 8.4 Online Pharmacies
  • 8.5 Other Distribution Channels

9 Global Expectorant Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Expectorant Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Abbott Laboratories
  • 12.2 Astrazeneca Plc.
  • 12.3 Acella Pharmaceuticals LLC
  • 12.4 Cipla Limited
  • 12.5 Beckman Coulter Inc.
  • 12.6 Mylan N.V.
  • 12.7 GSK plc
  • 12.8 Glenmark Pharmaceuticals Limited
  • 12.9 Johnson and Johnson
  • 12.10 Novartis International AG
  • 12.11 Merck KGaA
  • 12.12 Pfizer inc
  • 12.13 Sanofi SA
  • 12.14 Vernalis plc
  • 12.15 Proctor and Gamble Co
  • 12.16 Dahur india Ltd
  • 12.17 Teva Pharmaceutical Industries Ltd.
  • 12.18 Tris Pharma Inc.
  • 12.19 Aurobindo Pharma Ltd
  • 12.20 Biocon

List of Tables

  • Table 1 Global Expectorant Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Expectorant Drugs Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Expectorant Drugs Market Outlook, By Prescription Drug (2021-2030) ($MN)
  • Table 4 Global Expectorant Drugs Market Outlook, By Over The Counter (Otc) (2021-2030) ($MN)
  • Table 5 Global Expectorant Drugs Market Outlook, By Dosage Form (2021-2030) ($MN)
  • Table 6 Global Expectorant Drugs Market Outlook, By Oral Solid (2021-2030) ($MN)
  • Table 7 Global Expectorant Drugs Market Outlook, By Oral Liquid (2021-2030) ($MN)
  • Table 8 Global Expectorant Drugs Market Outlook, By Inhalant (2021-2030) ($MN)
  • Table 9 Global Expectorant Drugs Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 10 Global Expectorant Drugs Market Outlook, By Secretion Enhancer (2021-2030) ($MN)
  • Table 11 Global Expectorant Drugs Market Outlook, By Potassium Citrate (2021-2030) ($MN)
  • Table 12 Global Expectorant Drugs Market Outlook, By Sodium Citrate (2021-2030) ($MN)
  • Table 13 Global Expectorant Drugs Market Outlook, By Ammonium Chloride (2021-2030) ($MN)
  • Table 14 Global Expectorant Drugs Market Outlook, By Mucolytics (2021-2030) ($MN)
  • Table 15 Global Expectorant Drugs Market Outlook, By Bromhexine (2021-2030) ($MN)
  • Table 16 Global Expectorant Drugs Market Outlook, By Ambroxol (2021-2030) ($MN)
  • Table 17 Global Expectorant Drugs Market Outlook, By Carbocisteineurine (2021-2030) ($MN)
  • Table 18 Global Expectorant Drugs Market Outlook, By Acetyl Cysteine (2021-2030) ($MN)
  • Table 19 Global Expectorant Drugs Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 20 Global Expectorant Drugs Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 21 Global Expectorant Drugs Market Outlook, By Drug Store (2021-2030) ($MN)
  • Table 22 Global Expectorant Drugs Market Outlook, By Retail Store (2021-2030) ($MN)
  • Table 23 Global Expectorant Drugs Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 24 Global Expectorant Drugs Market Outlook, By Other Distribution Channels (2021-2030) ($MN)
  • Table 25 Global Expectorant Drugs Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Expectorant Drugs Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 27 Global Expectorant Drugs Market Outlook, By Speciality Centres (2021-2030) ($MN)
  • Table 28 Global Expectorant Drugs Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 29 Global Expectorant Drugs Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.